目次
第1章 グローバル合成生物学市場 エグゼクティブサマリー
1.1. グローバル合成生物学市場規模および予測（2022年～2032年）
1.2. 地域別概要
1.3. 分野別概要
1.3.1. 製品別
1.3.2. 技術別
1.3.3. 用途別
1.3.4. エンドユース別
1.4. 主要トレンド
1.5. 不況の影響
1.6. アナリストの推奨および結論
第2章 世界の合成生物学市場の定義と調査の前提条件
2.1. 調査の目的
2.2. 市場の定義
2.3. 調査の前提条件
2.3.1. 対象範囲と除外範囲
2.3.2. 制限事項
2.3.3. 供給サイド分析
2.3.3.1. 供給可能性
2.3.3.2. インフラ
2.3.3.3. 規制環境
2.3.3.4. 市場競争
2.3.3.5. 経済的実現可能性（消費者視点
2.3.4. 需要側分析
2.3.4.1. 規制枠組み
2.3.4.2. 技術的進歩
2.3.4.3. 環境への配慮
2.3.4.4. 消費者意識と受容
2.4. 推定方法
2.5. 調査対象年
2.6. 通貨換算レート
第3章 世界の合成生物学市場のダイナミクス
3.1. 市場推進要因
3.1.1. さまざまな分野における用途の増加
3.1.2. ゲノム編集技術の進歩
3.1.3. 持続可能性への注目が高まる
3.2. 市場の課題
3.2.1. インフラと規制の障壁
3.2.2. 研究開発費の高騰
3.3. 市場の機会
3.3.1. バイオベース経済における用途の拡大
3.3.2. 官民連携の増加
第4章 世界の合成生物学市場の業界分析
4.1. ポーターのファイブフォースモデル
4.2. PESTEL分析
4.3. トップ投資機会
4.4. 破壊的トレンド
4.5. アナリスト推奨
第5章 製品別世界合成生物学市場規模および予測（2022年～2032年）
5.1. セグメントダッシュボード
5.2. 収益トレンド分析（10億米ドル）
5.2.1. 酵素
5.2.2. クローニング技術キット
5.2.3. その他
第6章 技術別世界合成生物学市場規模・予測（2022年～2032年）
6.1. 分野別ダッシュボード
6.2. 収益動向分析（10億米ドル）
6.2.1. PCR
6.2.2. ゲノム編集
6.2.3. その他
第7章 用途別世界合成生物学市場規模・予測（2022年～2032年）
7.1. セグメントダッシュボード
7.2. 収益トレンド分析（10億米ドル
7.2.1. 医療
7.2.2. 非医療
第8章 合成生物学の世界市場規模・予測（2022年～2032年）エンドユース別
8.1. セグメントダッシュボード
8.2. 収益トレンド分析（10億米ドル
8.2.1. バイオテクノロジー・製薬企業
8.2.2. 学術・研究機関
第9章 地域別合成生物学市場規模・予測（2022年～2032年）
9.1. 北米
9.1.1. 米国
9.1.2. カナダ
9.2. ヨーロッパ
9.2.1. 英国
9.2.2. ドイツ
9.2.3. フランス
9.2.4. イタリア
9.2.5. スペイン
9.2.6. 東欧
9.3. アジア太平洋
9.3.1. 中国
9.3.2. インド
9.3.3. 日本
9.3.4. オーストラリア
9.3.5. 韓国
9.3.6. RoAPAC
9.4. ラテンアメリカ
9.4.1. ブラジル
9.4.2. メキシコ
9.5. 中東およびアフリカ
9.5.1. サウジアラビア
9.5.2. 南アフリカ
9.5.3. RoMEA
第10章 競合情報
10.1. 主要企業のSWOT分析
10.1.1. Codexis, Inc.
10.1.2. Illumina, Inc.
10.1.3. Thermo Fisher Scientific, Inc.
10.2. トップ市場戦略
10.3. 企業プロフィール
Codexis, Inc.
Merck Kgaa (Sigma-Aldrich Co. Llc)
Illumina, Inc.
Novozymes
Bota Biosciences Inc.
Pareto Bio, Inc.
Creative Biogene.
Creative Enzymes.
Thermo Fisher Scientific, Inc.
New England Biolabs
Scarab Genomics, Llc
Enbiotix, Inc.
Synthego
Synthetic Genomics Inc.
Eurofins Scientific
第11章 研究プロセス
11.1. 研究プロセス
11.1.1. データマイニング
11.1.2. 分析
11.1.3. 市場推定
11.1.4. 検証
11.1.5. 発行
11.2. 研究属性

The global synthetic biology market is estimated to be valued at USD 13.83 billion in 2023, poised to expand with a robust CAGR of 17.30% from 2024 to 2032.

Synthetic biology, which has evolved into a transformative technology, is making significant strides across healthcare, energy, agriculture, and material industries. The market growth is driven by its emerging applications in multiplexed diagnostics, genome editing, and therapeutic innovations, which are unlocking new opportunities for industry stakeholders.

Synthetic biology's adoption gained unprecedented momentum during the COVID-19 pandemic as researchers utilized it to develop vaccines, test kits, and therapies. This period highlighted the versatility and potential of synthetic biology, particularly in enhancing vaccine development timelines. Moreover, advancements in genome editing tools and biofoundries have paved the way for bio-based economies, further broadening the applications of synthetic biology across industries like bioplastics, biofuels, and sustainable materials. Companies such as Bolt Threads and Modern Meadow exemplify this trend by integrating biotechnology to create eco-friendly materials for various commercial applications.

Synthetic biology’s growing importance is further underscored by strategic investments in research institutions and innovative product launches. For instance, the launch of the Rice Synthetic Biology Institute aims to catalyze breakthroughs that translate into societal benefits. However, the market's long-term success depends on addressing infrastructural and regulatory challenges through public-private partnerships and comprehensive governance frameworks.

Geographically, North America dominated the market in 2024, benefiting from robust public and private investments and a thriving research ecosystem. Asia Pacific is anticipated to register the fastest CAGR during the forecast period, fueled by industrialization and significant investments in healthcare and life sciences infrastructure. Key regions like Europe are leveraging synthetic biology for sustainable solutions in agriculture and energy, further diversifying its applications.

The global synthetic biology market is experiencing a paradigm shift, driven by advancements in genome editing, increased research funding, and a growing focus on sustainability. As industry players innovate and collaborate, the sector is set to witness transformative growth, offering immense opportunities across diverse sectors.

Major market players included in this report are:
• Codexis, Inc.
• Merck Kgaa (Sigma-Aldrich Co. Llc)
• Illumina, Inc.
• Novozymes
• Bota Biosciences Inc.
• Pareto Bio, Inc.
• Creative Biogene.
• Creative Enzymes.
• Thermo Fisher Scientific, Inc.
• New England Biolabs
• Scarab Genomics, Llc
• Enbiotix, Inc.
• Synthego
• Synthetic Genomics Inc.
• Eurofins Scientific

The detailed segments and sub-segment of the market are explained below:
By Product
• Enzymes
• Cloning Technologies Kits
• Others

By Technology
• PCR
• Genome Editing
• Others

By Application
• Healthcare
• Non-Healthcare

By End Use
• Biotechnology & Pharmaceutical Companies
• Academic and Research Institutes

By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Italy
• Spain
• Rest of Europe (ROE)
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific (RoAPAC)
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa (RoMEA)

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Content
Chapter 1. Global Synthetic Biology Market Executive Summary
1.1. Global Synthetic Biology Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product
1.3.2. By Technology
1.3.3. By Application
1.3.4. By End Use
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Synthetic Biology Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Synthetic Biology Market Dynamics
3.1. Market Drivers
3.1.1. Rise in Applications Across Diverse Sectors
3.1.2. Advancements in Genome Editing Technologies
3.1.3. Growing Focus on Sustainability
3.2. Market Challenges
3.2.1. Infrastructure and Regulatory Barriers
3.2.2. High Costs of R&D
3.3. Market Opportunities
3.3.1. Expanding Applications in Bio-Based Economies
3.3.2. Increasing Public-Private Collaborations
Chapter 4. Global Synthetic Biology Market Industry Analysis
4.1. Porter’s Five Force Model
4.2. PESTEL Analysis
4.3. Top Investment Opportunities
4.4. Disruptive Trends
4.5. Analyst Recommendations
Chapter 5. Global Synthetic Biology Market Size & Forecast by Product (2022-2032)
5.1. Segment Dashboard
5.2. Revenue Trend Analysis (USD Billion)
5.2.1. Enzymes
5.2.2. Cloning Technologies Kits
5.2.3. Others
Chapter 6. Global Synthetic Biology Market Size & Forecast by Technology (2022-2032)
6.1. Segment Dashboard
6.2. Revenue Trend Analysis (USD Billion)
6.2.1. PCR
6.2.2. Genome Editing
6.2.3. Others
Chapter 7. Global Synthetic Biology Market Size & Forecast by Application (2022-2032)
7.1. Segment Dashboard
7.2. Revenue Trend Analysis (USD Billion)
7.2.1. Healthcare
7.2.2. Non-Healthcare
Chapter 8. Global Synthetic Biology Market Size & Forecast by End Use (2022-2032)
8.1. Segment Dashboard
8.2. Revenue Trend Analysis (USD Billion)
8.2.1. Biotechnology & Pharmaceutical Companies
8.2.2. Academic and Research Institutes
Chapter 9. Global Synthetic Biology Market Size & Forecast by Region (2022-2032)
9.1. North America
9.1.1. U.S.
9.1.2. Canada
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. ROE
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. RoAPAC
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. RoMEA
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Codexis, Inc.
10.1.2. Illumina, Inc.
10.1.3. Thermo Fisher Scientific, Inc.
10.2. Top Market Strategies
10.3. Company Profiles
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

❖ 掲載企業 ❖

Codexis, Inc.、Merck Kgaa (Sigma-Aldrich Co. Llc)、Illumina, Inc.、Novozymes、Bota Biosciences Inc.、Pareto Bio, Inc.、Creative Biogene.、Creative Enzymes.、Thermo Fisher Scientific, Inc.、New England Biolabs、Scarab Genomics, Llc、Enbiotix, Inc.、Synthego、Synthetic Genomics Inc.、Eurofins Scientificなど

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer